American Society of Hirudotherapy

Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article

Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024) · Cardiovascular Therapeutics

Review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE ModerateSystematic reviewBivalirudin: drug studies

Study Profile

Design
narrative systematic review of randomized controlled trials comparing heparin and bivalirudin anticoagulation in patients undergoing PCI for STEMI, NSTEMI, and unstable angina (Tangshan Gongren Hospital, China; Wuhan University; Harvard T.H. Chan)
Scope
Bivalirudin (synthetic hirudin-derived direct thrombin inhibitor) anticoagulation during PCI
Main result
Bivalirudin generally associated with lower bleeding rates than heparin in PCI for ACS; ischemic outcome equivalence varies by trial and ACS subtype; review reinforces clinical equipoise in some patient subgroups; demonstrates how synthetic hirudin-derivative pharmacology is studied via rigorous Phase-III pathways

Key Findings

  • Bivalirudin generally associated with lower bleeding than heparin in PCI for ACS
  • Trial-by-trial heterogeneity in ischemic-event outcomes
  • Bivalirudin is a synthetic hirudin derivative (Angiomax) with established FDA approval
  • Demonstrates the drug-regulatory pathway distinct from K040187 device pathway
  • Useful pedagogical reference for explaining FDA drug vs FDA device distinctions

Limitations

  • Narrative synthesis without quantitative meta-analysis
  • Cited RCTs span multiple decades and PCI eras
  • Generalization across STEMI / NSTEMI / unstable angina subgroups limited
  • No new primary data
  • Not directly applicable to whole-leech hirudotherapy

Clinical Implications

Wang 2024 provides contemporary clinical-pharmacology context for bivalirudin — the synthetic hirudin derivative — within interventional cardiology. For ASH, the review serves as a regulatory and educational reference for distinguishing FDA-approved drug indications (synthetic hirudin derivatives) from the FDA K040187 device indication (whole-leech therapy). No direct US hirudotherapy clinical-practice implications.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.